Novartis to show diverse oncology franchise at ASCO

ZURICH (Reuters) – Swiss drugmaker Novartis is hoping key cancer data on both its marketed products as well as promising drugs in its early pipeline will show it can pack a punch in the oncology field at a major industry meeting later this week. The Basel-based group, which trails local rival Roche in oncology, will present late-stage data on its drug Afinitor in postmenopausal women with advanced breast cancer as well as two late-stage studies on its blood cancer drug Tasigna in patients with Philadelphia chromosome-positive chronic myeloid leukaemia. …